Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Joel Brothers"'
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTBackground: T-prolymphocytic leukemia (T-PLL) is an aggressive hematologic malignancy. A portion of patients can be cured with alemtuzumab induction followed by allogeneic hematopoietic stem cell transplant, but patients who relapse after tra
Externí odkaz:
https://doaj.org/article/2fab398806a24985a9f7976cb6305edf
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Undifferentiated pleomorphic sarcoma (UPS), a subtype of soft tissue sarcoma (STS), is an uncommon malignancy associated with a poor prognosis. As with other forms of sarcoma, surgical resection remains the only form of treatment with curative potent
Externí odkaz:
https://doaj.org/article/09198af9a5424caf86f0ffb853df6fee
Autor:
Won Jin Jeon, Jasmine Nguyen, Dani Ran Castillo, Kiwon Park, Joel Brothers, Anthony Nguyen, Hamid Mirshahidi
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522211509
Introduction Pembrolizumab (Keytruda) is a monoclonal antibody against the programmed cell death-1 (PD-1) receptor on lymphocytes, which is one of the immune checkpoint inhibitors (ICIs) approved for multiple solid and hematologic malignancies. Altho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41e73720c40064be43c1d89988d911f5
https://doi.org/10.1177/10781552221150936
https://doi.org/10.1177/10781552221150936